Myeloproliferative Disorders Drugs/Treatment Market Size – By Disorder Type (Ph+ CML, Ph- MPN [Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis]), Drug Class (Tyrosine Kinase, JAK), Route of Administration, End-use & Forecast, 2024 – 2032

Myeloproliferative Disorders Drugs/Treatment Market Size – By Disorder Type (Ph+ CML, Ph- MPN [Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis]), Drug Class (Tyrosine Kinase, JAK), Route of Administration, End-use & Forecast, 2024 – 2032

Myeloproliferative Disorders Drugs/Treatment Market Size

Myeloproliferative Disorders Drugs/Treatment Market size was valued at USD 9.3 billion in 2023 and is expected to grow at a CAGR of 3.2% between 2024 and 2032. The market is experiencing significant growth due to the availability of novel drugs and a robust pipeline that has broadened the treatment options and stimulated innovation for rare disease treatment. Additionally, the rising incidence of myeloproliferative disorders, attributed to an aging population, changing lifestyles, and increased public awareness, further boosts market growth.
 

For instance, the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute estimates that approximately 20,000 people are diagnosed with a myeloproliferative neoplasm (MPN) each year in the U.S., with around 295,000 people living with an MPN. Moreover, the growing awareness about MPDs among both patients and healthcare providers is leading to early diagnosis and treatment, driving market growth.
 

Myeloproliferative disorder treatment refers to therapeutic interventions designed to manage and mitigate the symptoms and progression of myeloproliferative disorders, a group of rare haematological conditions characterized by the overproduction of blood cells in the bone marrow.
 

Myeloproliferative Disorders Drugs/Treatment Market Trends

• Growing focus on R&D activities by the pharmaceutical and biotech companies has significantly propelled the growth of the myeloproliferative disorder treatment.
   
• The escalated research to address the patient's need for effective treatment options has led to the discovery and development of innovative therapeutic approaches, including targeted therapies like JAK inhibitors, that offer improved efficacy and tolerability profiles.
   
• For instance, in May 2023, PharmaEssentia announced the commencement of its ECLIPSE PV Phase IIIb clinical trial for ropeginterferon alfa-2b-njft (BESREMi) in treating polycythemia vera.
   

Myeloproliferative Disorders Drugs/Treatment Market Analysis

Based on the disorder type, the market is categorized into Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), Philadelphia chromosome-negative (Ph-) myeloproliferative neoplasms (MPNs), and other disorder types. The Ph-MPNs are further classified as polycythemia vera, essential thrombocythemia, and myelofibrosis. The Ph-MPNs segment held over 91.7% of the market share in 2023.
 

• High market share of Ph- MPNs can be attributed to the relatively high prevalence of these disorders.
   
• Targeted therapies, especially directed at the abnormal JAK signaling pathway, have greatly transformed MPN treatment, notably the Ph-MPNs subtype, providing effective disease management and symptom alleviation for numerous patients.
   
• Furthermore, the expanding focus on the molecular mechanisms underlying Ph-MPNs has spurred the development of innovative therapies targeting specific mutations, consolidating their stronghold in the treatment market for myeloproliferative disorders.

 

Based on drug class, the myeloproliferative disorders drugs/treatment market is classified into tyrosine kinase inhibitors, Janus kinase (JAK) inhibitors, hydroxyurea, and other drug classes. The JAK inhibitors segment is anticipated to witness high growth at a CAGR of 3.1% through 2032.
 

• JAK inhibitors have emerged as the cornerstone of treatment in the myeloproliferative disorder drugs/ treatment market due to their efficacy in managing symptoms and disease progression.
   
• With the inherent property of targeting the dysregulated JAK-STAT signaling pathway, these drugs effectively alleviate symptoms and reduce spleen size in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia.
   
• Moreover, growing research focus on introducing effective treatment JAK drugs for the rare hematological disorder has further solidified their dominance in the market as preferred therapeutic agents for myeloproliferative disorders.
   

Based on the route of administration, the myeloproliferative disorders drugs/treatment market is classified into oral and injectable. The oral route segment is projected to cross USD 10.1 billion by 2032.
 

• Oral route offers convenience and flexibility to patients, enabling self-administration at home and reducing the need for frequent hospital visits. Additionally, oral therapies often have better patient adherence compared to injectable or intravenous treatments.
   
• Further, the availability of oral formulations for targeted therapies, such as JAK inhibitors solidifies the oral route's prominence in the treatment of myeloproliferative disorders.
   

Based on the end-use

the myeloproliferative disorders drugs/treatment market is classified into hospitals, specialty clinics, and other end-users. Hospital segment dominated around USD 4.6 billion revenue in 2023.
 

• Hospitals hold a prominent position in the myeloproliferative disorder treatment market due to their comprehensive healthcare facilities and specialized medical expertise.
   
• Patients with myeloproliferative disorders often require complex diagnostic evaluations, ongoing monitoring, and tailored treatment plans, which are efficiently provided within hospital settings.
   
• Moreover, hospitals have access to advanced technologies, interdisciplinary teams of healthcare professionals, and specialized resources necessary for managing the diverse spectrum of myeloproliferative disorders effectively.
   
• Therefore, hospitals have emerged as the primary providers for delivering comprehensive care and managing the treatment of myeloproliferative disorders.

 

North America dominated the global myeloproliferative disorders drugs/treatment market accounted for 41.9% of the market share in 2023.
 

• North America asserted dominance in the myeloproliferative disorder treatment market due to advanced healthcare infrastructure and facilities, facilitating early diagnosis and access to innovative treatments.
   
• Moreover, strong regulatory frameworks and favorable reimbursement policies contribute to market growth.
   
• Furthermore, extensive R&D activities, coupled with increasing awareness among healthcare professionals and patients, drive the adoption of advanced treatment modalities in the region.
   
• Thus, the aforementioned factors together contribute to North America's dominance in the myeloproliferative disorder treatment market.
   

Myeloproliferative Disorders Drugs/Treatment Market Share

Several key players are intensely involved in R&D activities aimed at introducing cutting-edge treatments for myeloproliferative disorders. These companies prioritize the development of targeted therapies such as JAK inhibitors in their pursuit of capturing market share. Additionally, they actively pursue collaborative research efforts and seek market authorization for effective treatment options to establish and uphold their leading position in the fiercely competitive market landscape.
 

Myeloproliferative Disorders Drugs/Treatment Market Companies

Prominent players operating in the myeloproliferative disorders drugs/treatment industry are as mentioned below

• AbbVie Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• GlaxoSmithKline plc (GSK)
• GL Pharma GmbH
• Incyte Corporation
• Janssen Biotech, Inc. (Johnson & Johnson)
• MorphoSys AG
• Mylan N.V. (Viatris)
• Novartis Pharmaceuticals Corporation (Novartis AG)
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
   

Myeloproliferative Disorders Drugs/Treatment Industry News

• In January 2024, GSK plc received marketing authorization grant by the European Commission for momelotinib, intended for patients with primary myelofibrosis experiencing disease-related splenomegaly or moderate to severe anaemia. This authorization established a new treatment option with a distinct mechanism of action for the patients within the European Union, offering potential therapeutic benefits.
   
• In August 2021, Bristol Myers Squibb received full Marketing Authorization by the European Commission for Inrebic, enabling its use in treating splenomegaly or associated symptoms in adult patients with specific types of myelofibrosis. The approval helped the company market its product across Europe.
   

The myeloproliferative disorders drugs/treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 - 2032 for the following segments

Click here to Buy Section of this Report

Market, By Disorder Type

• Philadelphia chromosome-positive (Ph+) CML
• Philadelphia chromosome-negative (Ph-) MPNs
  • Polycythemia vera
  • Essential thrombocythemia
  • Myelofibrosis 
• Other disorder types

Market, By Drug Class

• Tyrosine kinase inhibitors
• Janus kinase inhibitors
• Hydroxyurea
• Other drug classes

Market, By Route of Administration

• Oral
• Injectable

Market, By End-use

• Hospitals
• Specialty clinics
• Other end-users

The above information has been provided for the following regions and countries

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa